Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study

Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019

(2023) Rui Wang et al.   BMJ Open

IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality

(2022) Raja Atreya et al.   Journal of Crohns & Colitis

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease

(2021) Bruce E. Sands et al.   GASTROENTEROLOGY

Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

(2021) Jia-Feng Wu   Gut and Liver

Personalized Medicine with IL-23 Blockers: Myth or Reality?

(2021) Zoë S Gottlieb et al.   Journal of Crohns & Colitis

Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease

(2020) Derek H. W. Little et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology

(2020) Konstantinos Papamichael et al.   CURRENT OPINION IN RHEUMATOLOGY

Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease

(2020) Rahel Ehrenberg et al.   Journal of Managed Care & Specialty Pharmacy

The four epidemiological stages in the global evolution of inflammatory bowel disease

(2020) Gilaad G. Kaplan et al.   Nature Reviews Gastroenterology & Hepatology

Ulcerative Colitis: Shifting Sands

(2019) Geert R. A. M. D’Haens et al.   Drugs in research & development

Real‐world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review

(2019) Shahnaz Khan et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

(2019) Chao Chen et al.   INFLAMMATORY BOWEL DISEASES

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

(2019) Christopher Andrew Lamb et al.   GUT

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

(2017) Siew C Ng et al.   LANCET

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme

(2016) S M Babineaux et al.   BMJ Open

Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015

(2016) Victoria Higgins et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

(2011) Natalie A. Molodecky et al.   GASTROENTEROLOGY

Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand

(2008) P. Anderson et al.   CURRENT MEDICAL RESEARCH AND OPINION